Despite the widespread success of CAR T therapies, there have been challenging immunologic side effects such as cytokine release syndrome and neurotoxicity, which can now be mitigated with immune modulators and anti-inflammatory strategies.
The investment will fund new and expanded manufacturing facilities in California, Indiana, Massachusetts, Pennsylvania, and a location to be announced soon.
Under the 10-year deal, the contract manufacturer will provide production services at its Holly Springs, North Carolina facility for Regeneron’s biologic medicines.
